About our Program

Vanderbilts Independent Vascular Surgery Residency Program is approved by the Surgical Residency Review Committee (S-RRC) to graduate one resident annually. In addition to two fellows, the Division of Vascular Surgery includes five full-time vascular surgeons, one nurse practitioner, and two nurse clinical specialists. Faculty in vascular surgery have individual interests and expertise that provide patient care for all vascular diseases and conditions. These include peripheral arterial disease, carotid disease, visceral and renovascular disorders, as well as aneurysm disease of the thorax, abdomen, and extremities. Minimally invasive techniques are routinely applied in the management of peripheral interventions as well as the management of aneurysms.

Vanderbilt University Medical Center boasts 1,105 total beds, including 834 in Vanderbilt Hospital and 271 in the Monroe-Carell Jr. Childrens Hospital. Vanderbilt's 56 adult and 16 pediatric ORs perform over 51,000 surgeries annually. The Division of Vascular Surgery is part of the Vanderbilt Heart and Vascular Institute. This allows consolidation of clinical care for patients with cardiovascular disease in a single location with all specialists involved at hand to maximize both patient care and educational experiences. Each year, the Division of Vascular Surgery provides comprehensive care to approximately 6,000 patients who suffer from vascular diseases and conditions. Division Chief Thomas Naslund, M.D., directs an IAC-accredited noninvasive vascular laboratory that performs 5,000 vascular studies on an annual basis and is supported by five full- or part-time vascular technologists (RVTs).

Under the direction of Colleen Brophy, M.D., the division has a robust basic science research program. Dr. Brophys research has centered on enhancing patency of vascular bypass grafts. Among other discoveries, Dr. Brophys laboratory has identified a protein that is felt to be involved with relaxation of smooth muscle associated with vascular bypass grafts and other smooth muscle tissue. These efforts are funded through NIH and the Veterans Administration and are being expanded through bioengineering collaborative efforts to develop therapeutic agents in the treatment of fibrosis, inflammatory disorders, and epithelial cancers.